Detection of Mismatch Repair Deficiency in Colorectal Cancers: Is It Really Time to Eliminate Immunohistochemistry?

Detection of Mismatch Repair Deficiency in Colorectal Cancers: Is It Really Time to Eliminate Immunohistochemistry?

Related Articles

• CORRESPONDENCE: Reply to G. Le Flahec et al
  

  • Joanne Ngeow and
  • Charis Eng

  JCO JCO699405; published online on October 17, 2016;
  • [Full Text]
  • [PDF]
• CORRESPONDENCE: Reply to G. Le Flahec et al
  

  • Zsofia K. Stadler and
  • Leonard B. Salt

  •  Thus, for patients undergoing either an IHC or NGS analysis of their tumors, decisions on charges, as opposed to costs, by either laboratories or payers may well dictate which manner of testing for MMR status is more cost effective. Duplication of effort, however, is always more costly, and for those patients whose tumors will as a matter of course undergo assessment via an NGS panel for RAS or BRAF or for other reasons, the additional performance of MMR IHC is likely to constitute an unnecessary expense that can and should be avoided.

  JCO JCO699413; published online on October 17, 2016;
  
  

  • [Full Text]
  • [PDF]

REFERENCES

1. 1.↵
   1. Stadler ZK,
   2. Battaglin F,
   3. Middha S,
   4. et al.

   (2016) Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol 34:2141–2147.

   Abstract/FREE Full Text
2. 2.↵
   1. Le DT,
   2. Uram JN,
   3. Wang H,
   4. et al.

   (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520.

   CrossRefMedlineGoogle Scholar
3. 3.↵
   1. National Comprehensive Cancer Network

   , NCCN clinical practice guidelines in oncology (NCCN guidelines): Genetic/familial high-risk assessment—Colorectal. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
4. 4.↵
   1. Stoffel EM,
   2. Mangu PB,
   3. Limburg PJ

   (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk–colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Oncol Pract 11:e437–e441.

   FREE Full Text
5. 5.↵
   1. Uguen A,
   2. Guéguen P,
   3. Legoupil D,
   4. et al.

   (2015) Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Hum Pathol 46:1582–1591.

   CrossRefMedlineGoogle Scholar
6. 6.↵
   1. Nolan S,
   2. Arnason T,
   3. Drucker A,
   4. et al.

   (2014) The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Appl Immunohistochem Mol Morphol 22:e8–e13.

   CrossRefMedlineGoogle Scholar
7. 7.↵
   1. Turchini J,
   2. Andrici J,
   3. Sioson L,
   4. et al.

   NRASQ61R mutation-specific immunohistochemistry is highly specific for either NRASQ61R or KRASQ61R mutation in colorectal carcinoma. Appl Immunohistochem Mol Morphol, [epub ahead of print on February 9, 2016].

   Google Scholar
8. 8.↵
   1. Colling R,
   2. Wang LM,
   3. Soilleux E

   (2016) Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: A diagnostic test accuracy study. J Clin Pathol 69:398–402.

   Abstract/FREE Full Text